



US006734166B1

(12) **United States Patent**  
**Croom, Jr. et al.**

(10) **Patent No.:** **US 6,734,166 B1**  
 (45) **Date of Patent:** **May 11, 2004**

- (54) **METHOD OF REDUCING ALUMINUM LEVELS IN THE CENTRAL NERVOUS SYSTEM**
- (75) Inventors: **Warren J. Croom, Jr.**, Cary, NC (US); **Brian M. Berg**, Sanford, NC (US); **Ian L. Taylor**, Kiawah Island, SC (US)
- (73) Assignees: **North Carolina State University**, Raleigh, NC (US); **MUSC Foundation for Research Development**, Charleston, SC (US)
- (\*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

- (21) Appl. No.: **09/499,980**
- (22) Filed: **Feb. 8, 2000**
- (51) **Int. Cl.**<sup>7</sup> ..... **A61K 38/16**; A61K 38/10; A61K 38/05
- (52) **U.S. Cl.** ..... **514/12**; 514/2; 514/13; 514/14; 514/15; 514/16; 514/17; 530/300; 530/324; 530/325; 530/326; 530/327; 530/328; 530/329
- (58) **Field of Search** ..... 514/12, 13, 14, 514/15, 16, 17, 2; 530/324–329, 309

- (56) **References Cited**
- U.S. PATENT DOCUMENTS
- |           |     |        |                        |         |
|-----------|-----|--------|------------------------|---------|
| 5,385,915 | A   | 1/1995 | Buxbaum et al. ....    | 514/313 |
| 5,604,203 | A   | 2/1997 | Balasubramaniam .....  | 514/12  |
| 5,663,192 | A * | 9/1997 | Bruns et al. ....      | 514/420 |
| 5,716,828 | A   | 2/1998 | Roses et al. ....      | 435/6   |
| 5,912,227 | A   | 6/1999 | Coom, Jr. et al. ....  | 514/12  |
| 5,916,869 | A   | 6/1999 | Croom, Jr. et al. .... | 514/2   |

- FOREIGN PATENT DOCUMENTS
- WO WO-94/22467 A1 \* 10/1994

- OTHER PUBLICATIONS
- Gulya et al., [D–Pen2, D–Pen5]enkephalin, a d opioid agonist, reduces aluminum content in the rat central nervous system, *Neuroscience* (1995) 66(2):499–506.\*
- Alom et al. 1990. Cerebrospinal Fluid Neuropeptide Y in Alzheimer’s Disease. *Eur Neurol* 30:207–210.
- Beal et al. 1986. Neuropeptide Y Immunoreactivity is Reduced in Cerebral Cortex in Alzheimer’s Disease. *Annals of Neurology* 20:282–288.
- Chan–Palay et al. 1985. Cortical Neurons Immunoreactive with Antiserum Against Neuropeptide Y are Altered in Alzheimer’s–Type Dementia. *The Journal of Comparative Neurology* 238:390–400.
- Davies et al. 1990. A Quantitative Assessment of Somatostatin–like and Neuropeptide Y–like Immunostained Cells in the Frontal and Temporal Cortex of Patients with Alzheimer’s Disease. *Journal of the Neurological Sciences* 96:59–73.

Edvinsson et al. 1993. Neuropeptides in Cerebrospinal Fluid of Patients with Alzheimer’s Disease and Dementia with Frontotemporal Lobe Degeneration. *Dementia* 4:167–171.

Gabriel et al. 1996. Neuropeptide Deficits in Schizophrenia vs. Alzheimer’s Disease Cerebral Cortex. *Biological Psychiatry* 39:82–91.

Heilig et al. 1995. Cerebrospinal Fluid Neuropeptides in Alzheimer’s Disease and Vascular Dementia. *Biological Psychiatry* 38:210–216.

Koide et al. 1995. Plasma Neuropeptide Y is Reduced in Patients with Alzheimer’s Disease. *Neuroscience Letters* 198:149–151.

Martel et al. 1990. Neuropeptide Y Receptor Binding Sites in Human Brain. Possible Alteration in Alzheimer’s Disease. *Brain Research* 519:228–235.

Martignoni et al. 1992. Cerebrospinal Fluid Norepinephrine, 3–methoxy–4–hydroxyphenylglycol and Neuropeptide Y Levels in Parkinson’s Disease, Multiple System Atrophy and Dementia of the Alzheimer Type. *J. Neural Transm Park Dis Dement Sect* 4:191–205.

Minthon et al. 1996. Correlation Between Clinical Characteristics and Cerebrospinal Fluid Neuropeptide Y Levels in Dementia of the Alzheimer Type and Frontotemporal Dementia. *Alzheimer Disease and Associated Disorders* 10:197–203.

Minthon et al. 1997. Somatostatin and Neuropeptide Y in Cerebrospinal Fluid: Correlations with Severity of Disease and Clinical Signs in Alzheimer’s Disease and Frontotemporal Dementia. *Dementia and Geriatric Cognitive Disorders* 8:232–239.

Rao et al. 1999. Neuropeptide Y Structure is Modulated by Aluminium in the Hypothalamus. *Alzheimer’s Reports* 2:99–103.

Unnerstall et al. 1989. Alterations in the Density of [<sup>125</sup>I] Peptide YY Binding Sites in the Hippocampus in Alzheimer’s Disease. *Society for Neuroscience Abstracts* 15:861 Abstract 344.19.

Wikkelsö et al. 1991. Neuropeptides in Cerebrospinal Fluid in Normal–Pressure Hydrocephalus and Dementia. *Eur Neurol* 31:88–93.

Berg, et al., *Peptide YY Administration Decreases Brain Aluminum in the Ts65Dn Down Syndrome Mouse Model, Growth, Development & Aging*, vol. 64, pp. 3–19 (2000).

\* cited by examiner

*Primary Examiner*—Gabriele Bugaisky  
 (74) *Attorney, Agent, or Firm*—Myers, Bigel, Sibley & Sajovec, P.A.

(57) **ABSTRACT**

A method of reducing aluminum concentrations in the central nervous system of a subject (e.g., a patient afflicted with Alzheimer’s disease or at risk of developing Alzheimer’s disease) comprises administering to subject a PYY receptor agonist in an amount effective to reduce aluminum concentrations, levels or amounts in the central nervous system of the subject. Compositions useful for carrying out the method are also disclosed.